Full Press Release Details
NEW YORKandCARLSBAD, Calif.,Jan. 31, 2022/PRNewswire/ --Pfizer Inc.(NYSE:PFE) and Ionis Pharmaceuticals, Inc.(NASDAQ:IONS) today announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG).